C07D 475/00
Heterocyclic compounds containing pteridine ring systems
C07D475/00 (Heterocyclic compounds containing pteridine ring systems) appears on 657 US grants and 664 published applications in this corpus.
Search patents in C07D- Granted patents
- 657
- Published applications
- 664
- Assignees
- 380
- Inventors
- 1,803
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 11 | 0 |
| 1977 | 1 | 0 |
| 1978 | 9 | 0 |
| 1979 | 6 | 0 |
| 1980 | 5 | 0 |
| 1981 | 4 | 0 |
| 1982 | 6 | 0 |
| 1983 | 5 | 0 |
| 1984 | 4 | 0 |
| 1985 | 5 | 0 |
| 1986 | 7 | 0 |
| 1987 | 8 | 0 |
| 1988 | 5 | 0 |
| 1989 | 6 | 0 |
| 1990 | 8 | 0 |
| 1991 | 12 | 0 |
| 1992 | 7 | 0 |
| 1993 | 9 | 0 |
| 1994 | 17 | 0 |
| 1995 | 9 | 0 |
| 1996 | 8 | 0 |
| 1997 | 7 | 0 |
| 1998 | 12 | 0 |
| 1999 | 11 | 0 |
| 2000 | 9 | 0 |
| 2001 | 15 | 3 |
| 2002 | 12 | 10 |
| 2003 | 8 | 30 |
| 2004 | 13 | 29 |
| 2005 | 16 | 19 |
| 2006 | 13 | 30 |
| 2007 | 16 | 34 |
| 2008 | 14 | 26 |
| 2009 | 11 | 22 |
| 2010 | 23 | 31 |
| 2011 | 19 | 22 |
| 2012 | 22 | 22 |
| 2013 | 24 | 31 |
| 2014 | 21 | 35 |
| 2015 | 26 | 36 |
| 2016 | 32 | 36 |
| 2017 | 25 | 29 |
| 2018 | 17 | 29 |
| 2019 | 27 | 30 |
| 2020 | 17 | 26 |
| 2021 | 17 | 33 |
| 2022 | 10 | 21 |
| 2023 | 18 | 22 |
| 2024 | 20 | 21 |
| 2025 | 20 | 28 |
| 2026 | 10 | 9 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C07D 475/02Heterocyclic compounds containing pteridine ring systems: with an oxygen atom directly attached331
- C07D 475/06Heterocyclic compounds containing pteridine ring systems: with a nitrogen atom directly attached213
- C07D 475/12Containing pteridine ring systems condensed with carbocyclic rings or ring systems60
Recent patents
- PIKfyve kinase inhibitors22 Sep 2026US 12,741,960 B2Acurastem Incorporated
- Nitrogen-branched non-linear pegylated lipid containing a tertiary amine and application thereof18 Aug 2026US 12,708,675 B2Xiamen Sinopeg Biotech Co., Ltd.
- Pharmaceutically acceptable salts of sepiapterin26 May 2026US 12,637,465 B2PTC Therapeutics MP, Inc.
- Compound used as RET kinase inhibitor and application thereof19 May 2026US 12,629,358 B2Tyk Medicines, Inc.
- Folate salts for medical use12 May 2026US 12,622,913 B2Aprofol AG
- Carbon dioxide absorbent and carbon dioxide separation device24 Sep 2026US 2026/0284584 A1Kabushiki Kaisha Toshiba
- Pharmaceutically acceptable salts of sepiapterin3 Sep 2026US 2026/0258045 A1PTC Therapeutics MP, Inc.
- Nanomaterials containing constrained lipids and uses thereof13 Aug 2026US 2026/0232587 A1Georgia Tech Research Corporation
- Gamma polyglutamated aminopterin and uses thereof23 Jul 2026US 2026/0207609 A1L.E.A.F. Holdings Group LLC
- Plk1 degradation inducing compounds with increased rigidity16 Jul 2026US 2026/0199367 A1Uppthera, Inc.
Most cited
By later US patents
- Lipid formulation340US 8,158,601 B2Alnylam Pharmaceuticals, Inc. · 2012
- Nucleosidic and non-nucleosidic folate conjugates297US 6,335,434 B12002
- Kinase inhibitors175US 6,831,175 B2Abbott Laboratories · 2004
- Certain alkylene diamine-substituted heterocycles126US 6,506,762 B1Neurogen Corporation · 2003
- Lipid formulation126US 8,802,644 B2Tekmira Pharmaceuticals Corporation · 2014